

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

An investigation into the regulation of the topoisomerase II α promoter in breast cancer cells exposed to doxorubicin

A thesis presented to Massey University in partial fulfillment of the
requirement for the degree of Doctor of Philosophy in Biochemistry

Kirsty Ann Allen

2003

Dedication

This thesis is dedicated to my parents, Gary and Sandra Allen, and to my twin sister Kim Allen for all their support and encouragement over the last four years.

Acknowledgments

I would like to thank my supervisors Kathryn Stowell, Richard Isaacs and John Tweedie for all their expertise, enthusiasm and support that made this study possible. I would like to also thank the occupants of the Twilight Zone especially Carole Flyger, Robyn Marston, Natisha Magan and Chrissie Down for their patience and tolerance.

I acknowledge the financial support of the New Zealand Cancer Society, the Taranaki Branch of the Cancer Society, the Goodman Family Trust and the Institute of Molecular BioSciences, Massey University that made this research possible.

Abstract

Chemotherapeutic drugs, such as doxorubicin, are some of the most effective agents for the treatment of breast cancer. Acquired resistance to these drugs often develops, however, and may preclude effective treatment. Such resistance is multifactorial in origin, but may include down-regulation of topoisomerase II α (topo II α) - an essential enzyme involved in normal DNA metabolism and a target for some of the anticancer drugs. A reduction in the levels of this enzyme is thought to reduce DNA damage induced by the drug-topo II α complex and so increases the chances of survival.

The mechanisms involved in this down-regulation and the development of resistance to doxorubicin are the focus of this study. Stable breast cancer cell lines, containing deletion constructs of the topo II α promoter linked to the hGH reporter gene, were exposed to doxorubicin and both the reporter and endogenous gene expression were analysed in the surviving cells. It was shown that the reporter and endogenous topo II α gene expression in the cell line containing the full length topo II α promoter construct was no longer correlated in the surviving cells negating the use of this experimental system. Instead the endogenous expression of topo II α and putative regulatory factors were investigated.

Data suggest that specific cell lines show a down-regulation in the levels of the topo II α protein. These changes were not due to changes in cellular proliferation rates, cell cycle profile or promoter sequence. Selected cell lines were analysed for changes in the relative amounts of specific transcription factors with putative roles in topo II α gene regulation and for the expression of proteins proposed to have a role in the development of drug resistance. In specific cell lines, a reduction in topo II α protein levels correlated with alterations in the relative amounts of NF-YA and/or Sp1. It was shown that the drug efflux pumps MDR1 and MRP1, as well as the heat shock factor Hsp70 were not involved in the survival of cells that were exposed to the drug. *In vivo* footprinting was attempted to detect changes in the *in vivo* binding of proteins to the topo II α promoter after short term drug exposure.

Abbreviations

A	adenine
a.a	amino acid
AC	adenylyl cyclase
AP-1-4	activator protein-1-4
ATF	activating transcription factor
ATP	adenosine triphosphate
bp	base pair
BSA	bovine serum albumin
C	cytosine
CaCO-2	human colon carcinoma cell line
cAMP	cyclic adenosine monophosphate
CAPS	3-(cyclohexylamino)-1-propanesulfonic acid
cDNA	complementary DNA
CDK1	cyclin-dependent kinase 1
CDP	CCAAT displacement protein
C/EBP	CCAAT enhancer binding protein
CEM	human leukemic cell line
CKII	casein kinase II
cpm	counts per minute
C-terminal	carboxyl terminal
CTF (NF-1)	CCAAT transcription factor
CTP	cytosine triphosphate
DAG	diacylglycerol
DBD	DNA-binding domain
DEPC	diethyl pyrocarbonate
DMSO	dimethyl sulphoxide
DNase I	deoxyribonuclease I
dNTPs	deoxynucleoside triphosphates
dox ^R	doxorubicin-resistant
DTT	dithiothreitol

<i>E. coli</i>	<i>Escherichia coli</i>
EDTA	ethylene diamine tetra-acetate
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
Egr-1	early growth response protein-1
ELISA	enzyme-linked immunosorbent assay
ER	estrogen receptor
ERE	estrogen response element
ERK	extracellular signal-regulated kinase
FACS	fluorescence activated cell sorting
FCS	fetal calf serum
G	guanine
G418	neomycin sulphate
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
GCG	Genetics Computing Group
GRE	glucocorticoid responsive element
GTP	guanosine triphosphate
HAT	histone acetyltransferase
HeLa	human cervical carcinoma cell line
HEPES	N-2-hydroxyethyl piperazine-N'-2-ethane sulfonic acid
HepG2	human hepatocarcinoma cell line
HFM	histone fold motif
hGH	human growth hormone
HL-60	human promyelocytic leukemia cell line
hr	hour
hRPB11/13	human RNA polymerase II subunit 11/13
HSE	heat shock element
HSF	heat shock factor
Hsp70	Heat shock protein 70
HSP-CBF	Heat shock protein - CCAAT binding protein
ICB	inverted CCAAT box
ICB90	ICB binding protein 90

IgG	immunoglobulin G
IP3	inositol triphosphate
JNK	jun N-terminal kinase
JNKK	JNK kinase
K562	human erythroleukemic cell line
kb	kilobase
LMP	ligation-mediated PCR
MAPK	mitogen-activated protein kinase
MAPKK	MAPK kinase
MAPKKK	MAPK kinase kinase
MEK	MAPK kinase
MEM	modified Eagle's media
MCF-7	mammary epithelial carcinoma cell line
MDA-MB-231	mammary epithelial carcinoma cell line
MDR1	multidrug resistance protein 1
MDR3	multidrug resistance protein 3
MES-SA	human sarcoma cell line
MMLV	moloney murine leukemia virus
Mnase I	micrococcal nuclease
MRP1	multiple resistance-associated protein 1
MW	molecular weight
NADH	nicotinamide adenine dinucleotide
NF- κ B	nuclear factor- κ B
NFAT	nuclear factor of activated T cells
NF-Y	nuclear factor Y
NF-YA	A subunit of NF-Y
NF-YAL	NF-YA long isoform
NF-YAS	NF-YA short isoform
NF-YB	B subunit of NF-Y
NF-YC	C subunit of NF-Y
NIH3T3	murine fibroblast (Swiss 3T3) cell line
NLS	nuclear localization sequence

nt	nucleotide
N-terminal	amino terminal
ONPG	o-Nitrophenol β -D-Galacto-pyranoside
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline
PBSE	phosphate buffered saline EDTA
PCR	polymerase chain reaction
pGL3B	pGL3-Basic
pGL2C	pGL2-Control
P-gp	P-glycoprotein
PKA	protein kinase A
PKC	protein kinase C
PLC	phospholipase C
PMSF	phenyl methane sulfonyl fluoride
PVDF	polyvinyl difluoride
pSV- β -gal	pSV- β -galactosidase expression vector
RNase	ribonuclease
ROS	reactive oxygen species
RT	reverse transcriptase
RT-PCR	reverse transcription PCR
S/T	serine/threonine
SAPK	stress-activated protein kinase
SDS	sodium dodecyl sulphate
SEK	SAPK kinase
SH2	src homology domain 2
SH3	src homology domain 3
Sp1	specificity protein 1
Sp3	specificity protein 3
Stat	Signal Transducers and Activators of Transcription
SV40	Simian virus 40
T	thymine
$t_{1/2}$	half life

T25/T75	25/75 cm ² tissue culture vented flasks
TAE	Tris acetate EDTA
TAFs	TBP-associated factors
TBE	Tris Boric acid EDTA
TBP	TATA-box binding protein
TBST	Tris buffered saline triton X-100
TEMED	N,N,N',N'-Tetramethylethylenediamine
T _m	melting temperature
topo II α	topoisomerase II α
topo II β	topoisomerase II β
TPA	12- <i>O</i> -tetradecanoylphorbol 13-acetate
Tris	Tris-(hydromethyl) aminomethane
tsp	transcription start point
TTP	thymidine triphosphate
UV	ultra violet light
VP-16 ^R	etoposide-resistant
VM-26 ^R	teniposide-resistant
YB-1	Y-box binding protein-1

List of Figures

	page
Figure 1.1	The structure of the topo II α protein 4
Figure 1.2	Proposed model of the catalytic cycle of topo II α 6
Figure 1.3	Diagram of the transcription factors proposed to interact with specific elements of the topo II α promoter 8
Figure 3.1	The experimental system to identify specific regions involved in transcriptional regulation of promoter X 54
Figure 3.2	The topo II α promoter constructs used in this research 56
Figure 3.3	Timecourse of the hGH protein secreted by the MDA1964 cells before and after 100% confluence 64
Figure 3.4	Immunoblot of whole cell extracts from freely proliferating and cells that had been 100% confluent for 12-18 hours 65
Figure 3.5	The real time RT-PCR experiment investigating the amounts of topo II α and hGH mRNA in freely proliferating and 100% confluent MDA1964 cells 67
Figure 3.6	The FACS analysis of MDA1964 cells exposed to doxorubicin 70
Figure 3.7	Immunoblots detecting topo II α in whole cell extracts from the MDA1964, MDA144, MCF-7-1964 and MCF-7-144 cell lines 76
Figure 4.1	Immunoblots of the NF-YA isoforms present in MDA-MB-231, MCF-7, HepG2, HeLa, CaCO-2 and K562 cell lines 83
Figure 4.2	Summary of the immunoblot experiments to determine the relative amounts of topo II α and the relative proportion of NF-YAL in MDA-MB-231 and MCF-7 cell lines 86
Figure 4.3	Immunoblots detecting topo II α , Sp1, Sp3 and NF-YA in whole extracts from the MDA1964 and MDA144 cell lines 88
Figure 4.4	Graph of the immunoblot results from the MDA1964 cell lines and MDA144 cell lines 89

Figure 4.5	Immunoblots detecting topo II α , Sp1, Sp3 and NF-YA in whole cell extracts from the MCF-71964 and MCF-7144 cell lines	91
Figure 4.6	Graphs of the immunoblot results of MCF-7-1964 and MCF-7-144 cell lines	92
Figure 4.7	Graphs of the immunoblot results from the frozen and thawed D2, E1 and F1 cell lines	94
Figure 5.1	FACS analysis of MDA1964 control, A1 and A2 cell lines	105
Figure 5.2	RT-PCR to detect MDR1 mRNA in selected MDA1964 cell lines	107
Figure 5.3	Real time RT-PCR experiment investigating MRP1 mRNA levels in selected MDA1964 and MDA144 cell lines	108
Figure 5.4	Graph of immunoblot results detecting Hsp70 protein in the parental MCF-7, MCF-7-1964 and MCF-7-144 cell lines	109
Figure 5.5	Immunoblot detecting Hsp70 protein in the MDA144 and MCF-7-144 cell lines	111
Figure 6.1	Diagram of the DNase I footprinting experiment	118
Figure 6.2	Diagram of the experimental protocol for ligation-mediated PCR	119
Figure 6.3	Result of the DNase I nuclei digestion experiment	121
Figure 6.4	The primers used in the <i>in vivo</i> footprinting experiment	122
Figure 6.5	An <i>in vivo</i> footprinting experiment investigating the changes to the topo II α promoter after short term doxorubicin exposure	124
Figure 7.1	Model of the regulation of the topo II α promoter in the surviving cell lines	131
Figure 7.2	The putative transcription factor binding sites in the initial 1000 bp of the human topo II α promoter	134
Figure 7.3	Diagram of the MAPK, PKA and PKC-mediated signaling pathways	137

List of Tables

		page
Table 3.1	Summary of the plasma doxorubicin concentration seen in patients after doxorubicin treatment	53
Table 3.2	Summary of the real time RT-PCR experiments investigating topo II α and hGH mRNA before and after 100% confluence	67
Table 3.3	The percentage of cells in the G ₀ /G ₁ , S and G ₂ /M phases in the control and doxorubicin-exposed cells	70
Table 3.4	The initial and final (after freezing) hGH/cell values for the MDA1964 and MDA144 cell lines	72
Table 3.5	The initial and final (after freezing) hGH/cell values for MCF-7-1964 and MCF-7-144 cell lines	73
Table 3.6	Description of the cell lines used in the current study	74
Table 5.1	The doubling time and the relative amounts of the topo II α protein of specific MDA1964 and MDA144 cell lines	103
Table 7.1	Examples of transcription factors modified after doxorubicin exposure or in drug-resistant cell lines	135

Table of Contents

	page
Abstract	i
Abbreviations	ii
List of Figures	vii
List of Tables	ix

Chapter One Introduction

1.1	Introduction	1
1.2	Type I and II topoisomerases	1
1.3	The structure and function of topo IIα	3
1.4	The post translational regulation of topo IIα activity	5
1.5	Transcription regulation of eukaryotic promoters	7
1.5.1	Human topoisomerase II α promoter	7
1.5.2	Topo II α regulation during the cell cycle, during differentiation and confluence arrest	10
1.5.3	Regulation of topo II α during stress conditions	11
1.6	The mechanism of topo II poisons	11
1.6.1	Doxorubicin	12
1.7	The role of topo IIα in drug resistance	13
1.7.1	Alterations in topo II α catalytic activity in resistant cell lines	14

1.7.2	Alterations to the amounts of topo II α in resistant cell lines	15
1.7.2.1	Alterations to topo II α copy number in resistant cell lines	16
1.7.2.2	Regulation of the topo II α promoter in drug-resistant cell lines	16
1.8	Transcription factors Sp1, Sp3 and NF-Y	17
1.8.1	Sp1 (Specificity factor 1)	17
1.8.2	Sp3 (Specificity Protein 3)	18
1.8.3	NF-Y (nuclear factor Y)	19
1.9	Role of topo IIβ in drug resistance	21
1.10	The development of tumour cell resistance to chemotherapeutic drugs	21
1.10.1	MDR1 (multidrug resistance protein 1)	21
1.10.2	MDR3 (multidrug resistance protein 3)	22
1.10.3	MRP1 (multidrug resistance-associated protein)	22
1.10.4	Heat shock proteins	23
1.11	The current study	24
1.11.1	p53	24
1.11.2	Estrogen receptor	25
1.11.3	Experimental outline	26

Chapter Two Materials and Methods

2.1	Materials	27
2.2	Methods	30
2.2.1	Preparation of reporter constructs	30
2.2.1.1	Polymerase Chain Reaction	30

2.2.1.2	Restriction endonuclease digests	30
2.2.1.3	Purification of the digestion products	30
2.2.1.4	Ligation of vector and insert and transformation	31
2.2.1.5	Subcloning of the topoisomerase II α constructs into pGL3Basic (pGL3B)	31
2.2.1.6	Isolation of plasmid DNA	32
2.2.1.7	Large scale preparation of plasmid DNA	32
2.2.1.8	Quantification of DNA	32
2.2.1.9	Sequencing of DNA	33
2.2.2	The routine maintenance, passage and use of tissue culture cell lines	33
2.2.2.1	Preparation of tissue culture media	33
2.2.2.2	Establishment of cell lines from frozen stocks or after initial receipt of the cell lines	34
2.2.2.3	Freezing of cells for liquid nitrogen storage	34
2.2.2.4	Passage of cells for cell maintenance and transfections	34
2.2.2.5	Transient transfections	35
2.2.2.6	Luciferase assay	35
2.2.2.7	β -galactosidase assay	36
2.2.2.8	The production of stable breast cancer cell lines	36
2.2.2.9	Assay for human growth hormone (hGH)	37
2.2.2.10	Screening for the topoisomerase II α stables	37
2.2.2.11	Exposure of the cells to doxorubicin	37
2.2.2.12	Determining the hGH: cell ratio	37
2.2.2.13	Preparation of cells for FACS analysis	38
2.2.2.14	Determination of population doubling time	38
2.2.3	RT-PCR and real time RT-PCR analysis	39
2.2.3.1	The isolation of RNA	39
2.2.3.2	The production of cDNA products by reverse transcription	39
2.2.3.3	Primers and PCR conditions	40

2.2.3.4	Real time RT-PCR using the LightCycler™	40
2.2.4	The immunoblot procedure	41
2.2.4.1	The preparation of cell extracts	41
2.2.4.2.	Protein gel and transfer protocols for topo II α , Sp1, Sp3, NF-YA, α -tubulin, topo II β , P-gp, MRP1 and Hsp70 proteins	42
2.2.4.3	Immunodetection	43
2.2.5	<i>In vivo</i> footprinting	44
2.2.5.1	Isolation of nuclei	44
2.2.5.2	DNase I digestion	44
2.2.5.3	Alkaline gel electrophoresis	45
2.2.5.4	Primer extension	45
2.2.5.5	The ligation reaction	45
2.2.5.6	Extension product capture	46
2.2.5.7	PCR amplification	46
2.2.5.8	The production of the DNA sequencing ladder	47
2.2.5.9	Gel electrophoresis	47
2.2.5.10	Electroblotting	48
2.2.5.11	Probe synthesis	48
2.1.5.12	Hybridisation	48

Chapter Three Analysis of Drug-exposed Breast Cancer Cells

3.1	Introduction	50
3.2	Generation of doxorubicin 'resistant' breast cancer cell lines	51
3.3	Experimental design	52

3.4	Basal regulation of the topo IIα promoter in the breast cancer cell lines	55
3.4.1	Breast carcinoma cell lines	57
3.4.2	The sequencing of the topo II α promoter	57
3.4.3	Transient transfection with the -1964, -1861, -1463, -1163 -894, -617, -144, -101, -56 and pGL3B reporter constructs	59
3.4.4	Summary of basal regulation of topo II α	60
3.5	Verification of the reporter system	61
3.5.1	The production of stable cell lines containing the topo II α promoter deletion constructs	61
3.5.2	Investigation of the hGH reporter protein, endogenous topo II α mRNA and protein in stable cell lines	62
3.5.2.1	Analysis of the reporter gene expression before and after confluence	63
3.5.2.2	Endogenous topo II α gene expression in confluent and freely proliferating cells	65
3.5.2.3	Summary of endogenous topo II α and reporter gene expression	66
3.5.3	Analysis of the breast cancer cells treated with doxorubicin	69
3.5.3.1	Expression of hGH and topo II α mRNA and protein in the breast cancer cell lines	71
3.6	Discussion	77

Chapter Four Analysis of Transcription Factors in the Drug-exposed Breast Cancer Cells

4.1	Introduction	81
------------	---------------------	-----------

4.2	Analysis of long and short NF-YA isoforms, Sp1 and Sp3 in various cell lines	82
4.3	Analysis of transcription factors in parental stable cell lines	85
4.4	Analysis of transcription factors in the drug-exposed cell lines	87
4.4.1	The MDA1964 and MDA144 cell lines	87
4.4.2	The MCF-7-1964 and MCF-7-144 cell lines	90
4.4.3	Effect of freezing and thawing on surviving cell lines	93
4.5	Discussion	95
4.5.1	NF-Y and modulation of topo II α gene expression	97
4.5.2	Alterations in the amount of Sp1	99
4.5.3	Sp3 and topo II α regulation	100

Chapter Five Other Potential Resistance Mechanisms

5.1	Introduction	102
5.2	The analysis of the doubling time in the surviving cell lines	102
5.3	The analysis of cell cycle profile of selected surviving cell lines	103
5.4	The expression of genes implicated in drug resistance in breast cancer cells	104
5.4.1	Alterations in the expression of MDR1 in surviving cell lines	106
5.4.2	Alterations in the expression of MRP1 in surviving cell lines	107

5.4.3	Alterations to the relative amounts of the Hsp70 protein in the surviving cell lines	109
5.5	Discussion	110
5.5.1	Alterations of doubling time in selected surviving cell lines	110
5.5.2	Alterations to the cell cycle profile of selected surviving cell lines	112
5.5.3	The expression of MDR1 and MRP1 in the surviving cell lines	113
5.5.4	Hsp70 expression in the surviving cell lines	113
5.5.5	Expression of topo II β in the surviving cell lines	114

Chapter Six Development of an *in vivo* footprinting system

6.1	Introduction	116
6.2	Overview of <i>in vivo</i> footprinting	116
6.3	Ligation-mediated PCR	117
6.4	Method development : <i>in vivo</i> footprinting	119
6.4.1	DNase I digestion	120
6.4.2	The design of topo II α promoter primers	121
6.5	<i>In vivo</i> footprinting of the topo IIα promoter shortly after doxorubicin exposure	123

Chapter Seven Summary and Discussion

7.1	Experimental summary	126
------------	-----------------------------	------------

7.2	Model for the regulation of the topo IIα promoter	128
7.3	Potential role of other transcription factors in the modulation of the topo IIα promoter during or after drug exposure	132
7.4	Potential cell type-specific modulators of topo IIα expression between the MDA-MB-231 and MCF-7 cell lines	133
7.5	Signaling pathways activated by doxorubicin	136
7.6	Future directions	138
7.7	Conclusion	140

References	141
-------------------	------------

Appendices

1	Literature review of the basal transcription of the topo IIα promoter in different cell lines	180
2	Table of the mechanisms of drug action and resistance mechanisms	181
3	Examples of drug-resistant cell lines which have shown changes in the amounts of topo IIα or topo IIβ	182
4	Summary of the primers used in RT-PCR and real time RT-PCR	183

5	An example of a PCR "standard curve" used to determine the PCR efficiency of the PCR reaction in a real time RT-PCR experiment	184
6	Diagram of the vectors used in the current study	185
7	The sequence of the human topo II α promoter	186
8	Putative transcription factors binding sites in the human topo II α promoter	189
9	Optimization for transient transfection experiments	193
10	Summary of the results of transient transfection experiments	194
11	Summary of the immunoblot results for the MDA1964 and MDA144 cell lines	195
12	Summary of the immunoblot results for the MCF-7-1964 and MCF-7-144 cell lines	196
13	Comparison of the "before and after freezing" immunoblot results for the MDA1964 and MDA144 cell lines	197
14	Correlation between the doubling time and the relative amounts of topo II α protein for the MDA1964 and MDA144 cell lines	198
15	The expression of MDR1 and MDR3 mRNA in various cancer cell lines	199
16	The expression of MRP1 mRNA in various cancer cell lines	200
17	Example of a real time RT-PCR experiment to determine the levels of topo II α and hGH mRNA in confluent and freely proliferating cell lines	201